Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Juan M. Ferrero-Cafiero"'
Autor:
Tomás Pascual, Mafalda Oliveira, Eva Ciruelos, Meritxell Bellet Ezquerra, Cristina Saura, Joaquin Gavilá, Sonia Pernas, Montserrat Muñoz, Maria J. Vidal, Mireia Margelí Vila, Juan M. Cejalvo, Blanca González-Farré, Martin Espinosa-Bravo, Josefina Cruz, Francisco Javier Salvador-Bofill, Juan Antonio Guerra, Ana María Luna Barrera, Miriam Arumi de Dios, Stephen Esker, Pang-Dian Fan, Olga Martínez-Sáez, Guillermo Villacampa, Laia Paré, Juan M. Ferrero-Cafiero, Patricia Villagrasa, Aleix Prat
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Background: Preclinical data support a key role for the human epidermal growth factor receptor 3 (HER3) pathway in hormone receptor (HR)–positive breast cancer. Recently, new HER3 directed antibody drug conjugates have shown activity in breast canc
Externí odkaz:
https://doaj.org/article/0fe8923a3c164bc1a60918d97253ce3e
Autor:
Meritxell Bellet, Serafin Morales, Ariadna Gasol, Kepa Amillano, Nuria Chic, Xavier González-Farré, Patricia Villagrasa, Laia Paré, Claudette Falato, Paolo Nuciforo, Débora Martínez, Juan M Ferrero-Cafiero, Tomás Pascual, Aleix Prat, Carol Lange, Cristina Saura
Publikováno v:
Cancer Research. 82:P1-07
Background PgR expression is a biomarker of ER functionality, cellular progression to malignancy, and response to endocrine therapy (ET) in HR+ BC. Onapristone (ONA), a type 1 antiprogestin, was shown to have a single agent anti-tumor activity in pat
Autor:
Tomás Pascual, Maria Vidal, Mafalda Oliveira, Juan M Cejalvo, Estela Vega, Esther Sanfeliu, Sergi Ganau, Ana Julve, Esther Zamora, Ignacio Miranda, Ana Delgado, Begoña Bermejo, Luis de la Cruz, Claudette Falato, Manel Juan, Juan M Ferrero-Cafiero, Xavier González-Farré, Patricia Villagrasa, Aleix Prat
Publikováno v:
Cancer Research. 82:P2-14
Background Residual disease (RD) following neoadjuvant chemotherapy (NAC) in early HER2 negative breast cancer (BC) remains an unmet medical need. We hypothesized that combining T-VEC with Atezolizumab may offer clinical benefit in terms of residual
Autor:
Aleix Prat, Cristina Saura, Josefina Cruz, Esteban Nogales Fernández, Javier Salvador Bofill, Joaquin Gavilá, Maria José Bermejo-Perez, Vanesa Quiroga, Serafin Morales, Sonia Servitja, Ruben de Toro, Pilar Zamora, Patricia Galván, Nuria Chic, Débora Martínez, Fara Brasó-Maristany, Jordi Canes, Laia Paré, Juan M Ferrero-Cafiero, Tomás Pascual, Sonia Pernas
Publikováno v:
Cancer Research. 82:OT1-12
Background: Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 15-20% of breast cancers (BC). At the same time, HER2-low tumors (immunohistochemistry 1+ or 2+ with no gene amplification) comprise ~50% of all BC. Trastuzumab D
Autor:
Eva Ciruelos, Cristina Saura, Xavier González-Farré, Javier Salvador Bofill, Maria Vidal, Isabel Blancas, Elena López-Miranda, Maria Iglesias, Miriam Arumi, Mireia Margelí, Catarina Pulido, Serafin Morales, Fernando Henao, Pilar Sánchez, Sara Alves, Diogo Branco, Joan Manel Gasent, Pedro Sánchez-Rovira, Ana Godoy, José L. Passos-Coelho, Santiago Escrivá-de-Romaní, Juan M Ferrero-Cafiero, Tomás Pascual, Aleix Prat
Publikováno v:
Cancer Research. 82:OT2-27
Background HR+/HER2-negative BC represents ∼70% of all newly diagnosed breast tumors. BC is a clinically and biologically heterogeneous disease where intrinsic subtypes play a role. Non-luminal subtypes within HR+/HER2-negative disease do not benef
Autor:
Ignacio Miranda, Begoña Bermejo, Juan M Ferrero-Cafiero, Manel Juan, Patricia Villagrasa, Aleix Prat, Ana Delgado, Xavier Gonzalez, Maria Vidal, Tomás Pascual, Estela Vega, Ana Julve, Sergi Ganau, Juan Miguel Cejalvo, Jordi Canes, Luis de la Cruz-Merino, Mafalda Oliveira, Esther Zamora
Publikováno v:
Future Oncology. 16:1801-1813
New treatment strategies such as immune checkpoint inhibitors and oncolytic viruses are opening new possibilities in cancer therapy. Preliminary results in melanoma and other tumors showed that the combination of talimogene laherparepvec with an anti
Autor:
Aleix Prat, Juan M. Cejalvo, Laia Pare, Olga Martínez-Sáez, Mireia Margelí Vila, Claudette Falato, Josefina Cruz, Miriam Arumí de Dios, Maria J Vidal, Juan Antonio Guerra, Ana Maria Luna Barrera, Pablo Tolosa, Francisco Javier Salvador-Bofill, Sonia Pernas, Blanca Gonzáles-Farré, Esther Sanfeliu, Eva Ciruelos, Violeta Serra, Martin Espinosa-Bravo, Yann Izarzugaza, Stephen Esker, Pang-Dian Fan, Guillermo Villacampa, Juan M Ferrero-Cafiero, Tomás Pascual, Mafalda Oliveira
Publikováno v:
Cancer Research. 82:PD13-04
Introduction Patritumab deruxtecan (U3-1402; HER3-DXd) is a HER3-directed antibody drug conjugate with demonstrated clinically meaningful antitumor activity and acceptable safety profile in heavily pre-treated metastatic breast cancer (BC) with high
Autor:
F.J. Salvador Bofill, Mireia Margeli, Juan M Ferrero-Cafiero, Luis Manso, Aleix Prat, Mafalda Oliveira, Salvador Blanch, Xavier Gonzalez, T. Pascual, Charles M. Perou, D. Moreno, B. Adamo, Sonia Pernas
Publikováno v:
Annals of Oncology. 32:S515
Autor:
Antonia Perelló, Sonia Servitja, J. Ponce Lorenzo, Eva Ciruelos, P. Tolosa, Juan M Ferrero-Cafiero, J.M. Cejalvo, Juan Antonio Guerra, F.J. Salvador Bofill, Isabel Blancas, C. Albacar, Santiago Escrivá-de-Romaní, Sonia Pernas, Josefina Cruz, Cristina Rodríguez, Martínez Pérez, Esther Sanfeliu, Aurelio López, Santiago González-Santiago, Aleix Prat
Publikováno v:
Annals of Oncology. 32:S511
Autor:
S. Morales Murillo, C. Lange, Juan M Ferrero-Cafiero, T. Pascual, Aleix Prat, Meritxell Bellet, Patricia Villagrasa, Nuria Chic, C. Saura Manich, Kepa Amillano, A. Gasol Cudos, X. González-Farré
Publikováno v:
Annals of Oncology. 32:S36